International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 143-150
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Clinical Charactheristics and Treatment Results of Primary Gastrointestinal Lymphoma Patients: Single Center Experience
İnci ALACACIOĞLU1, Mehmet A. ÖZCAN1, Murat MERAL2, Özden PİŞKİN1, Fatih DEMİRKAN1, Güner H. ÖZSAN1, Sermin ÖZKAL3, Bülent ÜNDAR1
1Dokuz Eylül Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, İZMİR
2Dokuz Eylül Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, İZMİR
3Dokuz Eylül Üniversitesi Tıp Fakültesi, Patoloji Bilim Dalı, İZMİR
Keywords: Lymphoma, Gastrointestinal, MALT, Diffuse large B-cell lymphoma
Twenty-four primary gastrointestinal (GI) lymphoma patients diagnosed between September 1998 and April 2004 in hematology department of Dokuz Eylul University Faculty of Medicine were evaluated retrospectively. The female to male ratio of patients was 1/1 with a median age of 64 years. Mean follow-up period was 43.8 months. There were 18 patients (75%) with diffuse large B-cell lymphoma (DLBCL), 6 patients (25%) with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT/MZBHL). In 83.3% of patients, disease was limited to the stomach. 45.8% of the patients were in stage I-II and 54.2% in stage III-IV. The median overall survival (OS) was 60±20 months. The OS of patients with low and low/intermediate IPI score and OS of patients with stage I-II were higher than OS of patients with high/intermediate IPI score and OS of patients with stage III-IV (120±44.9 months x 34±26.1 months, p=0.01; 120±43.5 months x 25±10 months, p=0.001 respectively). There was no significant differencies between OS of the patients treated with chemotherapy alone and treated with chemotherapy and surgery in both DLBCL and MALT lymphoma group. In conclusion, GI system lymphoma is a heterogenous disease with variety of clinic and demographic features and optimal treatment is not yet established.
İnci ALACACIOĞLU1, Mehmet A. ÖZCAN1, Murat MERAL2, Özden PİŞKİN1, Fatih DEMİRKAN1, Güner H. ÖZSAN1, Sermin ÖZKAL3, Bülent ÜNDAR1
1Dokuz Eylül Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, İZMİR
2Dokuz Eylül Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, İZMİR
3Dokuz Eylül Üniversitesi Tıp Fakültesi, Patoloji Bilim Dalı, İZMİR
Keywords: Lymphoma, Gastrointestinal, MALT, Diffuse large B-cell lymphoma
Twenty-four primary gastrointestinal (GI) lymphoma patients diagnosed between September 1998 and April 2004 in hematology department of Dokuz Eylul University Faculty of Medicine were evaluated retrospectively. The female to male ratio of patients was 1/1 with a median age of 64 years. Mean follow-up period was 43.8 months. There were 18 patients (75%) with diffuse large B-cell lymphoma (DLBCL), 6 patients (25%) with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT/MZBHL). In 83.3% of patients, disease was limited to the stomach. 45.8% of the patients were in stage I-II and 54.2% in stage III-IV. The median overall survival (OS) was 60±20 months. The OS of patients with low and low/intermediate IPI score and OS of patients with stage I-II were higher than OS of patients with high/intermediate IPI score and OS of patients with stage III-IV (120±44.9 months x 34±26.1 months, p=0.01; 120±43.5 months x 25±10 months, p=0.001 respectively). There was no significant differencies between OS of the patients treated with chemotherapy alone and treated with chemotherapy and surgery in both DLBCL and MALT lymphoma group. In conclusion, GI system lymphoma is a heterogenous disease with variety of clinic and demographic features and optimal treatment is not yet established.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |